Moderna (MRNA) Stock Jumps 16% on Flu Vaccine Data and Analyst Upgrades

TLDR

• Shares of Moderna jumped more than 16% after Phase 3 trial results for its mRNA flu vaccine (mRNA-1010) were published in the New England Journal of Medicine, which showed the shot outperformed a standard-dose flu vaccine for adults aged 50 and older.
• Three analyst firms adjusted their outlooks for Moderna following the company’s Q1 2026 earnings release: Evercore ISI lifted its price target to $50, Goldman Sachs raised its target to $49, and Piper Sandler launched new coverage with a Buy rating.
• A cluster of hantavirus cases linked to a cruise traveling from Argentina to Cabo Verde briefly drew extra attention to Moderna’s early-stage hantavirus program, though analysts note there is no meaningful revenue opportunity tied to this development right now.
• The FDA has set an August 5 PDUFA goal date for a decision on mRNA-1010, with regulatory filings also under review by authorities in Europe, Canada, and Australia.
• Pfizer and BioNTech stopped recruiting participants for a large U.S. COVID vaccine trial focused on adults aged 50–64, citing low enrollment numbers.

---

(SeaPRwire) –   On Thursday, Moderna stock traded around $56, up more than 16% for the day. The rally was fueled by a combination of strong clinical data, a wave of analyst upgrades, and hantavirus-related headlines that caught investors’ attention.

Moderna, Inc. (MRNA)

The main driver of the gain is straightforward: Phase 3 trial results for Moderna’s mRNA flu vaccine candidate, mRNA-1010, were published in the New England Journal of Medicine. The data confirmed the vaccine met its pre-specified superiority benchmark against a licensed standard-dose seasonal flu vaccine for adults aged 50 and older.

This is a meaningful milestone to clear. Outperforming an already approved vaccine in a peer-reviewed journal gives Moderna’s regulatory application a solid foundation ahead of its key upcoming FDA decision.

The FDA has set August 5 as the PDUFA goal date for mRNA-1010. Regulatory filings are also under review in Europe, Canada, and Australia, so the vaccine could see a multi-market launch if it wins approvals.

Analyst upgrades added extra fuel to the stock’s rally. Evercore ISI lifted its price target from $35 to $50, Goldman Sachs raised its target from $43 to $49, and Piper Sandler initiated coverage with a Buy rating. All three updates came following Moderna’s Q1 2026 earnings release.

Hantavirus Headlines Added Unrelated Market Noise

A hantavirus outbreak among passengers on a Dutch-flagged cruise from Argentina to Cabo Verde briefly pushed Moderna higher during early trading. Eight cases were reported, including three deaths, with five confirmed as the Andes virus — the only hantavirus strain known to allow limited human-to-human transmission.

The WHO assessed the public health risk as low. Dr. Maria Van Kerkhove spoke directly at a Thursday press conference: “This is not the start of a COVID pandemic.”

Evercore ISI noted Moderna has a hantavirus research collaboration with Korea University dating back to 2023, but also issued clear caution. The firm said it sees “no meaningful revenue opportunity” from the recent outbreak headlines, and noted that Moderna’s hantavirus candidate “remains very early stage.” Analysts wrote that Moderna’s stock “tends to trade on outbreak headlines far beyond what is justified by the underlying commercial implications.”

In short: while hantavirus news grabbed attention, the flu vaccine data and analyst upgrades are the core factors that moved the stock.

Cruise Stocks Felt Downward Pressure

Cruise line stocks pulled lower on the back of hantavirus news. Royal Caribbean fell about 2% on the day, Carnival dropped a similar amount, Norwegian Cruise Line Holdings was down nearly 3%, and Viking Holdings and Lindblad Expeditions each fell around 2.5%.

On the competitive side, Pfizer and BioNTech halted enrollment for a large U.S. COVID vaccine trial targeting adults aged 50 to 64, citing low participation. This development may strengthen Moderna’s relative positioning in the next-generation vaccine space.

The broader market was supportive of gains, with the S&P 500 up 0.71%, the Dow up 0.21%, and the Nasdaq up 1.16%.

Moderna’s stock closed the prior trading day at $48.79. The August 5 FDA decision date for mRNA-1010 is now the next major catalyst on the calendar for the company.